| Theme | Pathophysiology and Treatment of Deranged Lipid Metabolism in Chronic Renal Failure | |
|---|---|---|
| Title | Therapy to improve the qualitative abnormalities of lipoproteins in chronic renal failure | |
| Publish Date | 1998/09 | |
| Author | Michiko Sakagashira | The Third Department of Internal Medicine, Wakayama Medical College |
| Author | Susumu Yukawa | The Third Department of Internal Medicine, Wakayama Medical College |
| [ Summary ] | In chronic renal failure, the main qualitative abnormality of lipoproteins is the change to modified low-density lipoproteins(modified LDL), such as oxidized LDL. It is important that modified LDL be related to the progress of atherosclerosis and its relationship to the patient's metabolic system. In fact, serum malondialdehyde (MDA) concentrations (MDA/TBARS) were significantly higher in hemodialysis patients than in control groups, and MDA concentrations in LDL were significantly higher in hemodialysis patients. After the treatment with an antioxidant, vitamin E (alpha-Tocopherol;alpha-Toc), the level of MDA in LDL tended to decrease, and abnormalities in LDL metabolism in macrophages improved. In the long term treatment of alpha-Toc, the level of the calcification of the aorta in hemodialysis patients was significantly lower than in untreated patients. Therefore we consider vitamin E as the medication of first choice, to improve lipid abnormalities in chronic renal failure. Further studies are needed to investigate the effects of probucol, vitamin C,and beta-carotene in chronic renal failure. |
|